The spectrum of mastocytosis.
Mastocytosis represents a spectrum of clinical disorders that results from an aberrant proliferation of tissue mast cells. This disease process may be confined to the skin (cutaneous mastocytosis) or may involve multiple organs (systemic mastocytosis). Parameters that are useful in differentiating cutaneous from systemic disorders include patient age, symptom complex, and clinical signs. A wide range of clinical symptoms may be encountered in patients with mastocytosis which result from the release of pharmacologically potent mast cell mediators. Distinct cutaneous patterns resulting from skin mast cell infiltrates can be helpful in identifying patients with systemic involvement. The diagnosis of mastocytosis is confirmed by demonstrating increased tissue mast cells in involved organs. The overall prognosis for patients with proliferative mast cell disease is relatively good, although a small percentage are at risk for developing a fatal neoplastic disorder (malignant mastocytosis). Treatment of mastocytosis is directed at both inhibiting mast cell degranulation and blocking the potential systemic effects of released secretory products. Future therapeutic advances depend upon an improved understanding of the basic mechanisms involved in mast cell mediator release and the forces that govern mast cell growth and development.
Tharp
M D
MD
D000328:Adult; D001847:Bone Diseases / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006529:Hepatomegaly / Q000473:pathology; D006632:Histamine / Q000378:metabolism / Q000652:urine; D006633:Histamine Antagonists / Q000627:therapeutic use; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D008206:Lymphatic Diseases / Q000473:pathology; D008297:Male; D008407:Mast Cells / Q000378:metabolism / Q000473:pathology / Q000502:physiology / Q000648:ultrastructure; D011701:PUVA Therapy; D011289:Preleukemia; D011379:Prognosis; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D013163:Splenomegaly / Q000473:pathology; D014582:Urticaria Pigmentosa / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000473:pathology
D005938:Glucocorticoids; D006633:Histamine Antagonists; D011448:Prostaglandin Antagonists; D006632:Histamine; D004205:Cromolyn Sodium; D004837:Epinephrine